Literature DB >> 16775501

Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia.

Helmy M Siragy1, Chun Xue, Randy L Webb.   

Abstract

The aim of this study was to determine if myocardial inflammation is increased after myocardial ischemia and whether angiotensin-converting enzyme inhibitors, calcium channel blockers, or diuretics decrease mediators of inflammation in rats with induced myocardial ischemia. Changes in cardiac interstitial fluid (CIF) levels of nitric oxide metabolites (NOX), cyclic guanosine 3',5'-monophosphate (cGMP), angiotensin II (Ang II), and tumor necrosis factor-alpha (TNF-alpha) were monitored with/without oral administration of benazepril, amlodipine, combined benazepril-amlodipine, or hydrochlorothiazide. Using a microdialysis technique, levels of several mediators of inflammation were measured after sham operation or 30-minute occlusion of the left anterior descending coronary artery. Compared with sham animals, levels of CIF NOX and cGMP were decreased in animals with ischemia (P < 0.001). Benazepril or amlodipine significantly increased NOX levels (P < 0.05 vs. untreated ischemia), but only benazepril significantly increased cGMP (P < 0.05). Combined benazepril-amlodipine further increased CIF NOX and cGMP (P < 0.001), compared with either drug alone. CIF Ang II and TNF-alpha in sham animals did not change significantly. In animals with ischemia, CIF Ang II and TNF-alpha increased progressively. Amlodipine alone, benazepril alone, or combined benazepril-amlodipine significantly reduced TNF-alpha (P < 0.01 for monotherapies and P < 0.001 for combination therapy). Hydrochlorothiazide did not cause significant changes in NOX, cGMP, or TNF-alpha. Combination benazepril-amlodipine may be beneficial for managing cardiac ischemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775501     DOI: 10.1097/01.fjc.0000211750.01326.b3

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  17 in total

1.  Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.

Authors:  Luis C Matavelli; Jiqian Huang; Helmy M Siragy
Journal:  J Cardiovasc Pharmacol       Date:  2012-03       Impact factor: 3.105

2.  Prehypertensive African-American women have preserved nitric oxide and renal function but high cardiovascular risk.

Authors:  Deborah L Feairheller; Kathleen M Sturgeon; Keith M Diaz; Praveen Veerabhadrappa; Sheara T Williamson; Deborah L Crabbe; Michael D Brown
Journal:  Kidney Blood Press Res       Date:  2010-07-13       Impact factor: 2.687

3.  Optimizing blood pressure control in patients with chronic kidney disease.

Authors:  Biff F Palmer; Andrew Z Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-07

4.  Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.

Authors:  Luis C Matavelli; Helmy M Siragy
Journal:  J Cardiovasc Pharmacol       Date:  2013-01       Impact factor: 3.105

5.  Beneficial effect of combination therapy using an angiotensin-converting enzyme inhibitor plus verapamil on circulating resistin levels in hypertensive patients with type 2 diabetes.

Authors:  Alberto F Rubio-Guerra; Hilda Vargas-Robles; Jose J Lozano Nuevo; Cesar I Elizalde-Barrera; Saul Huerta-Ramirez; Bruno A Escalante-Acosta
Journal:  Exp Clin Cardiol       Date:  2012

Review 6.  Ceramide: a common pathway for atherosclerosis?

Authors:  Jean Bismuth; Peter Lin; Qizhi Yao; Changyi Chen
Journal:  Atherosclerosis       Date:  2007-10-25       Impact factor: 5.162

Review 7.  Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker.

Authors:  George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

8.  Will the results of the ACCOMPLISH trial affect the recommendations of JNC 8?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-02       Impact factor: 3.738

9.  Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors.

Authors:  Alberto F Rubio-Guerra; David Castro-Serna; Cesar I Elizalde Barrera; Luz M Ramos-Brizuela
Journal:  Integr Blood Press Control       Date:  2009-11-23

Review 10.  Risk-based classification of hypertension and the role of combination therapy.

Authors:  Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.